Reported Earlier, BridgeBio's Acoramidis Shows 42% Reduction in Mortality and Heart Hospitalizations in ATTR-CM Study, New Drug Application Under FDA Review
Reported Earlier, BridgeBio's Acoramidis Shows 42% Reduction in Mortality and Heart Hospitalizations in ATTR-CM Study, New Drug Application Under FDA Review
据报道，BridgeBio的Acoramidis在ATTR-Cm研究中显示心衰和心脏住院率降低42％，新药申请正处于FDA审查中。
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, presented a post-hoc analysis evaluating the effect of acoramidis on the composite endpoint of ACM and recurrent CVH events in its Phase 3 ATTRibute-CM study in ATTR-CM at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024. ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational, near-complete, orally-administered, small molecule stabilizer of TTR.
BridgeBio Pharma, Inc.（纳斯达克：BBIO）（“BridgeBio”或“公司”），一家专注于遗传病的商业阶段生物制药公司，展示了对ACm和复发CVH事件的复合终点在其ATTR-Cm第3期ATTRibute-Cm研究中对acoramidis的影响的事后分析，该研究于2024年在美国心力衰竭协会（HFSA）年度科学会议上举行。 ATTRibute-Cm旨在评估acoramidis的疗效和安全性，这是一种调查性的近完整口服小分子TTR稳定剂。
"We are proud to share the results of this post-hoc analysis demonstrating a highly significant reduction in all...
“我们很自豪地分享了这项事后分析的结果...
登录免费看全文
登录/注册
资讯热榜
更新时间